Compare Cigna Corp (CI) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs Linde PLC — how do they compare? Cigna Corp trades at $272.3 (market cap $73.56B), while Linde PLC trades at $491.05 (market cap $227.01B). The key difference: Linde PLC is far larger — about 3.1× Cigna Corp's market cap, and Cigna Corp pays the higher dividend (2.24%). Which is the better fit depends on your goals.
| CI | LIN | |
|---|---|---|
Market Cap | $73.56B | $227.01B |
Sector | Health | Basic Materials |
52-Week High | $311.00 | $546.64 |
52-Week Low | $244.41 | $389.38 |
Enterprise Value | $98.27B | $250.13B |
Dividend Yield | 2.24% | 1.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $282.49, up 2.63% with strong earnings beats in recent quarters. The stock shows bearish technical signals but benefits from low valuation ratios like a P/E of 11.68 and P/S of 0.27. Recent Q2 2026 results exceeded expectations, with EPS of $7.78 beating estimates, and the company raised its full-year guidance to at least $30.45 adjusted EPS, reflecting robust growth in health services and insurance segments.
The outlook is positive due to consistent earnings outperformance and raised guidance, though technical weakness and competitive pressures pose risks. Analyst consensus is strongly bullish with a $338.90 price target, indicating ~20% upside potential from current levels, supported by dividend payments and institutional accumulation.
Linde (LIN) trades at $489.98, showing minimal daily change. The stock exhibits strong fundamentals with consistent earnings beats, a 20.43% net income margin, and robust cash flow. However, technical indicators signal a bearish short-term trend, with the price near the pivot point of $490. Recent news highlights sustainability leadership and Q1 2026 EPS growth of 10% year-over-year, though a DCF analysis from GuruFocus on June 1, 2026, suggested potential overvaluation at a $327 fair value.
The investment outlook is supported by solid profitability and a bullish analyst consensus with a $553.60 price target, but risks include elevated valuation multiples and increasing debt-to-asset ratios. The stock's near-term direction may hinge on Q3 2026 earnings versus the $4.53 estimate, with technical resistance at $493 posing a challenge to upside momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
